Project funded by the National Centre for Research and Development under the Smart Growth Operational Programme 2014–2020
Priority Axis IV: Increasing the Scientific and Research Potential
Action 4.1: Research and Development
Sub-action 4.1.1: “Strategic Research Programmes for the Economy”
Project value: PLN 2,354,428.75 (including PLN 282,302.00 in own contribution)
Funding amount: PLN 2,072,126.75
Project implementation period: 02/01/2020 – 30/06/2021
Principal Investigator: Dr. Ewelina Świderek
Łukasiewicz – PORT coordinator: Dr. hab. Jakub Siednienko
Consortium:
Łukasiewicz – PORT Polish Center for Technology Development – Consortium Leader
PURE BIOLOGICS S.A.
The aim of the project is to develop an innovative melanoma therapy based on an aptamer–cytostatic conjugate. Standard treatments for melanoma are characterized by limited therapeutic efficacy and a high risk of adverse effects. According to the latest report by the American Cancer Society, melanoma is the fifth most commonly diagnosed cancer in the United States in both men and women. The number of diagnosed cases continues to rise each year, underscoring the strong commercial potential for a novel therapy specifically targeting cancer cells. Furthermore, the project aligns with the global trend of developing new therapeutic strategies based on carrier–drug conjugates.
Ultimately, the direct beneficiaries of the proposed solution will be melanoma patients. Introducing a new targeted therapy focusing on a molecular marker expressed on tumor cell surfaces will address a significant unmet medical need in this field.
